A Phase 2 interventional study of Naproxen sodium/Caffeine (BAY2880376) and Naproxen sodium (Aleve) in Pain, Postoperative, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-09-01.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing naproxen in Pain, Postoperative — 2 open to participants now, 2 under way, 1 of them phase 3. Naproxen · Pain, Postoperative.
Among the 13 studies testing naproxen in Pain, Postoperative, this one is the 8th largest by enrollment, is the only one that started in 2019, is the only one in phase 2, and was the 8th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,240 are open to participants now.
Browse Pain, Postoperative studies →2 of the 13 studies testing naproxen in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:
Rothman Institute Orthopaedics · Sites in United States
Ages 18+ · Healthy volunteers
Rothman Institute Orthopaedics · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 675 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 328 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 4
First in 2008; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 193 is above the median of 75 across 4,854 interventional studies indexed under Pain, Postoperative.
Median enrollment 200 across the 13 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 7 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 5 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing naproxen in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The researchers in this study wanted to find out the optimal dose of Caffeine in the combination tablet of Naproxen Sodium and Caffeine that works in patients experiencing moderate to severe pain after having wisdom teeth removed. In the US, Naproxen has been marketed since 1976, and Naproxen Sodium has been approved for over-the-counter (OTC) use since 1994 for the temporary relief of minor aches and pains. Caffeine, which is generally consumed as coffee, tea or cocoa, has been shown to enhance the effectiveness of various pain relievers, and therefore is accepted as an additive to painkillers like aspirin and acetaminophen. Patients participating in this study underwent a surgery to remove 3 or 4 wisdom teeth. If the pain severity after the surgery met the study requirement, patients would receive oral tablet(s) of Naproxen Sodium and Caffeine, or Naproxen Sodium, or Caffeine, or placebo (drug with no active ingredient). Patients could also receive additional pain medication when needed. Researchers would also learn if the patients have any medical problems during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/medium low dose) after extraction of third molars
Drug: Naproxen sodium/Caffeine (BAY2880376)
Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/low dose) after extraction of third molars
Drug: Naproxen sodium/Caffeine (BAY2880376)
Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ medium low dose) plus one tablet of placebo after extraction of third molars
Drug: Naproxen sodium/Caffeine (BAY2880376)
Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ low dose) plus one tablet of placebo after extraction of third molars
Drug: Naproxen sodium/Caffeine (BAY2880376)
Participants received a single dose of one tablet of naproxen sodium (low dose) plus one tablet of placebo after extraction of third molars
Drug: Naproxen sodium (Aleve)
Participants received a single dose of two tablets of caffeine (medium low dose) after extraction of third molars
Drug: Caffeine
Participants received a single dose of two tablets of matching placebo after extraction of third molars
Drug: Placebo
Drug pages: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CaffeineStudies of CaffeineCaffeine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Tablet, oral, single dose
Tablet, oral, single dose
Tablet, oral, single dose
Tablet, oral, single dose
Sum of Pain Intensity Difference (SPID) Over 8 Hours
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 8 hours ranges from -80 to 80. A higher value indicates a better pain reduction.
Time frame: Up to 8 hours post dose
Sum of Pain Intensity Differences (SPIDs) From 0 to 2, 4 and 12 Hours Post-dose
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID 0-2 ranges from -20 to 20, SPID 0-4 ranges from -40 to 40 and SPID 0-12 ranges from -120 to 120. A higher value indicates a better pain reduction.
Time frame: Up to 2 hours, 4 hours and 12 hours post dose
Total Pain Relief (TOTPAR) Over 8 Hours
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 8 hours ranges from 0 to 32, a higher value indicates more pain relief.
Time frame: Up to 8 hours post dose
Total Pain Relief (TOTPAR) From 0 to 2, 4 and 12 Hours Post-dose
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR 0-2 ranges from 0 to 8, TOTPAR 0-4 ranges from 0 to 16, and TOTPAR 0-12 ranges from 0 to 48. A higher value indicates more pain relief
Time frame: Up to 2 hours, 4 hours and 12 hours post dose
Time to First Use of Rescue Medication
Time frame: Up to 12 hours post dose
The Cumulative Percentage of Participants Taking Rescue Medication
Time frame: Up to 12 hours post dose
Pain Intensity Difference (PID) at Each Evaluation
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement
Time frame: Up to 12 hours post dose
Peak Pain Intensity Difference (PID)
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). Participants circle a number (from 0 to 10) on the Numerical Rating Scale to indicate the severity the pain they are experiencing at baseline and at each post dose time point. For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score).
Time frame: Up to 12 hours post dose
Pain Relief Score at Each Evaluation
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief)
Time frame: Up to 12 hours post dose
Peak Pain Relief Score
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). At each post-dose time point, participants check the appropriate box (from 0 to 4) on the Categorical Pain Relief Rating Scale to indicate the relief from starting pain at the post dose time points.
Time frame: Up to 12 hours post dose
Global Assessment of the Investigational Product
Global assessment is performed either at 12 hours post-dose or immediately prior to the first intake of rescue medication. Global assessment is based on the question 'Overall, I would rate the study medication I received: 0=Poor, 1=Fair, 2=Good, 3=Very Good, 4=Excellent.'
Time frame: Up to 12 hours post dose
Number of Participants With Adverse Events
Time frame: Up to 5 days post dose
The Number of Participants With Clinically Significant Changes in Physical Examinations and Vital Signs
Time frame: Up to 5 days post dose
Study was conducted at a single center in United States with first participant first visit on 12-Nov-2019 and last participant last visit on 02-Mar-2020. Study was completed on 03-Mar-2020 (End of follow up, phone call).
| Milestone | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 32 | 32 | 32 | 32 | 32 | 16 | 17 |
| Completed | 32 | 31 | 32 | 32 | 32 | 16 | 17 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 8 hours ranges from -80 to 80. A higher value indicates a better pain reduction.
| Scores on a scale*hours | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| Sum of Pain Intensity Difference (SPID) Over 8 Hours | 35.45 ± 14.517 | 37.87 ± 16.876 | 30.70 ± 17.679 | 36.02 ± 14.825 | 29.95 ± 19.067 | 8.75 ± 21.465 | 6.03 ± 17.810 |
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID 0-2 ranges from -20 to 20, SPID 0-4 ranges from -40 to 40 and SPID 0-12 ranges from -120 to 120. A higher value indicates a better pain reduction.
| Scores on a scale*hours | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| SPID 0-2 | 8.30 ± 3.141 | 8.68 ± 3.789 | 7.17 ± 3.721 | 6.92 ± 3.501 | 6.05 ± 3.511 | 2.13 ± 4.060 | 1.16 ± 2.925 |
| SPID 0-4 | 18.02 ± 6.387 | 19.26 ± 8.019 | 15.58 ± 7.697 | 17.05 ± 7.232 | 14.33 ± 8.391 | 4.50 ± 9.604 | 2.59 ± 7.625 |
| SPID 0-12 | 50.58 ± 24.237 | 52.45 ± 27.305 | 44.80 ± 28.929 | 52.45 ± 23.022 | 43.08 ± 30.034 | 12.44 ± 32.059 | 1.15 ± 2.833 |
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 8 hours ranges from 0 to 32, a higher value indicates more pain relief.
| Scores on a scale*hours | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| Total Pain Relief (TOTPAR) Over 8 Hours | 19.58 ± 7.007 | 20.26 ± 7.673 | 17.41 ± 8.063 | 19.53 ± 6.448 | 16.27 ± 8.514 | 7.03 ± 9.283 | 5.44 ± 7.709 |
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR 0-2 ranges from 0 to 8, TOTPAR 0-4 ranges from 0 to 16, and TOTPAR 0-12 ranges from 0 to 48. A higher value indicates more pain relief
| Scores on a scale*hours | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| TOTPAR 0-2 | 4.83 ± 1.401 | 4.77 ± 1.731 | 4.22 ± 1.596 | 3.97 ± 1.436 | 3.52 ± 1.644 | 1.66 ± 1.767 | 1.06 ± 1.328 |
| TOTPAR 0-4 | 10.27 ± 2.750 | 10.29 ± 3.449 | 8.84 ± 3.286 | 9.28 ± 2.842 | 7.86 ± 3.813 | 3.59 ± 4.148 | 2.44 ± 3.281 |
| TOTPAR 0-12 | 28.20 ± 12.262 | 28.26 ± 12.690 | 25.13 ± 13.291 | 28.72 ± 10.678 | 22.95 ± 13.206 | 10.28 ± 13.882 | 8.44 ± 12.419 |
| hours | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| Time to First Use of Rescue Medication | NA (NA to NA) | NA (8.967 to NA) | NA (8.817 to NA) | NA (NA to NA) | NA (8.125 to NA) | 2.083 (1.275 to NA) | 2.125 (1.408 to NA) |
| Percentage of participants | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| 0.5 Hours Post-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 Hour Post-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1.5 Hours Post-Dose | 0 | 3.2 | 3.1 | 0 | 0 | 37.5 | 25.0 |
| 2 Hours Post-Dose | 0 | 3.2 | 3.1 | 0 | 0 | 50 | 37.5 |
| 3 Hours Post-Dose | 0 | 6.5 | 6.3 | 3.1 | 15.6 | 56.3 | 56.3 |
| 4 Hours Post-Dose | 3.1 | 6.5 | 9.4 | 3.1 | 18.8 | 56.3 | 68.8 |
| 5 Hours Post-Dose | 9.4 | 6.5 | 15.6 | 3.1 | 18.8 | 62.5 | 68.8 |
| 6 Hours Post-Dose | 9.4 | 9.7 | 18.8 | 6.3 | 21.9 | 68.8 | 68.8 |
| 7 Hours Post-Dose | 12.5 | 9.7 | 21.9 | 6.3 | 21.9 | 68.8 | 68.8 |
| 8 Hours Post-Dose | 15.6 | 9.7 | 21.9 | 9.4 | 21.9 | 68.8 | 75.0 |
| 9 Hours Post-Dose | 21.9 | 25.8 | 25.0 | 9.4 | 28.1 | 68.8 | 75.0 |
| 10 Hours Post-Dose | 25.0 | 25.8 | 28.1 | 15.6 | 31.3 | 68.8 | 75.0 |
| 11 Hours Post-Dose | 25.0 | 25.8 | 28.1 | 15.6 | 34.4 | 68.8 | 75.0 |
| 12 Hours Post-Dose | 25.0 | 29.0 | 28.1 | 18.8 | 34.4 | 75.0 | 75.0 |
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement
| Scores on a scale | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| 0.5 Hours Post-Dose | 2.3 ± 2.07 | 2.6 ± 1.82 | 2.1 ± 2.23 | 1.4 ± 1.56 | 1.5 ± 1.34 | 0.8 ± 0.98 | 0.5 ± 0.89 |
| 1 Hour Post-Dose | 4.2 ± 1.88 | 4.2 ± 2.44 | 3.7 ± 1.95 | 3.4 ± 2.39 | 2.9 ± 1.88 | 1.2 ± 2.26 | 0.6 ± 1.71 |
| 1.5 Hours Post-Dose | 4.9 ± 1.67 | 5.1 ± 2.26 | 4.3 ± 1.98 | 4.2 ± 2.32 | 3.7 ± 2.16 | 1.2 ± 2.79 | 0.7 ± 1.74 |
| 2 Hours Post-Dose | 5.1 ± 1.76 | 5.5 ± 2.20 | 4.3 ± 2.23 | 4.8 ± 2.23 | 4.1 ± 2.22 | 1.1 ± 2.67 | 0.5 ± 1 |
| 3 Hours Post-Dose | 5.0 ± 1.82 | 5.4 ± 2.27 | 4.3 ± 2.33 | 5.0 ± 2.29 | 4.0 ± 2.83 | 1.1 ± 2.85 | 0.6 ± 2.42 |
| 4 Hours Post-Dose | 4.8 ± 2.17 | 5.2 ± 2.59 | 4.1 ± 2.62 | 5.1 ± 2.27 | 4.3 ± 2.82 | 1.3 ± 3.11 | 0.9 ± 2.78 |
| 5 Hours Post-Dose | 4.7 ± 2.28 | 5.0 ± 2.42 | 4.0 ± 2.72 | 5.0 ± 2.25 | 4.1 ± 2.83 | 1.1 ± 3.14 | 1.0 ± 2.92 |
| 6 Hours Post-Dose | 4.6 ± 2.24 | 4.8 ± 2.42 | 3.8 ± 2.87 | 4.9 ± 2.40 | 3.9 ± 2.88 | 1.1 ± 3.19 | 1.0 ± 3.06 |
| 7 Hours Post-Dose | 4.3 ± 2.55 | 4.5 ± 2.45 | 3.8 ± 3.07 | 4.7 ± 2.31 | 3.9 ± 3.08 | 1.1 ± 3.36 | 0.8 ± 2.49 |
| 8 Hours Post-Dose | 4.0 ± 2.53 | 4.2 ± 2.65 | 3.7 ± 3.12 | 4.3 ± 2.29 | 3.7 ± 2.96 | 0.9 ± 2.95 | 0.7 ± 2.65 |
| 9 Hours Post-Dose | 3.8 ± 2.71 | 3.8 ± 3.12 | 3.6 ± 3.00 | 4.2 ± 2.45 | 3.6 ± 3.14 | 1.1 ± 3.09 | 0.8 ± 2.74 |
| 10 Hours Post-Dose | 3.8 ± 2.88 | 3.7 ± 3.04 | 3.4 ± 3.15 | 4.1 ± 2.60 | 3.3 ± 3.07 | 1.1 ± 3.07 | 0.9 ± 2.99 |
| 11 Hours Post-Dose | 3.8 ± 2.92 | 3.5 ± 3.02 | 3.6 ± 3.17 | 4.2 ± 2.79 | 3.1 ± 3.02 | 0.8 ± 2.99 | 0.9 ± 2.96 |
| 12 Hours Post-Dose | 3.8 ± 2.97 | 3.6 ± 3.06 | 3.5 ± 3.38 | 4.0 ± 2.92 | 3.1 ± 2.97 | 0.8 ± 3.00 | 0.9 ± 2.96 |
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). Participants circle a number (from 0 to 10) on the Numerical Rating Scale to indicate the severity the pain they are experiencing at baseline and at each post dose time point. For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score).
| Scores on a scale | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| Peak Pain Intensity Difference (PID) | 6.0 ± 1.53 | 6.2 ± 1.97 | 5.9 ± 2.01 | 6.3 ± 1.72 | 5.3 ± 2.57 | 2.7 ± 2.94 | 2.3 ± 2.98 |
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief)
| Scores on a scale | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| 0.5 Hours Post-Dose | 1.6 ± 1.08 | 1.5 ± 0.89 | 1.5 ± 1.02 | 0.9 ± 0.80 | 1.0 ± 0.74 | 0.6 ± 0.62 | 0.4 ± 0.63 |
| 1 Hours Post-Dose | 2.4 ± 0.84 | 2.3 ± 1.22 | 2.2 ± 0.91 | 2.0 ± 1.14 | 1.8 ± 0.91 | 0.9 ± 1.00 | 0.6 ± 0.81 |
| 1.5 Hours Post-Dose | 2.8 ± 0.64 | 2.8 ± 0.99 | 2.3 ± 0.87 | 2.4 ± 0.91 | 2.0 ± 1.05 | 0.9 ± 1.24 | 0.6 ± 0.73 |
| 2 Hours Post-Dose | 2.8 ± 0.85 | 2.9 ± 1.01 | 2.4 ± 1.01 | 2.6 ± 0.79 | 2.2 ± 1.01 | 0.8 ± 1.05 | 0.5 ± 0.82 |
| 3 Hours Post-Dose | 2.8 ± 0.79 | 2.8 ± 0.97 | 2.4 ± 1.04 | 2.6 ± 0.91 | 2.1 ± 1.21 | 0.9 ± 1.24 | 0.6 ± 1.09 |
| 4 Hours Post-Dose | 2.7 ± 1.07 | 2.7 ± 1.19 | 2.3 ± 1.16 | 2.7 ± 0.96 | 2.2 ± 1.26 | 1.0 ± 1.37 | 0.8 ± 1.18 |
| 5 Hours Post-Dose | 2.6 ± 1.16 | 2.6 ± 1.15 | 2.3 ± 1.27 | 2.7 ± 1.00 | 2.2 ± 1.24 | 0.9 ± 1.36 | 0.8 ± 1.18 |
| 6 Hours Post-Dose | 2.4 ± 1.16 | 2.6 ± 1.18 | 2.2 ± 1.35 | 2.7 ± 1.10 | 2.1 ± 1.30 | 0.9 ± 1.45 | 0.8 ± 1.24 |
| 7 Hours Post-Dose | 2.3 ± 1.34 | 2.5 ± 1.15 | 2.1 ± 1.38 | 2.5 ± 1.08 | 2.1 ± 1.29 | 0.9 ± 1.50 | 0.8 ± 1.28 |
| 8 Hours Post-Dose | 2.1 ± 1.33 | 2.3 ± 1.28 | 2.1 ± 1.46 | 2.4 ± 1.19 | 2.0 ± 1.28 | 0.8 ± 1.33 | 0.7 ± 1.25 |
| 9 Hours Post-Dose | 2.2 ± 1.40 | 2.1 ± 1.48 | 2.0 ± 1.45 | 2.3 ± 1.12 | 1.9 ± 1.41 | 0.9 ± 1.36 | 0.8 ± 1.34 |
| 10 Hours Post-Dose | 2.2 ± 1.51 | 2.0 ± 1.43 | 1.8 ± 1.42 | 2.3 ± 1.28 | 1.8 ± 1.41 | 0.9 ± 1.36 | 0.8 ± 1.34 |
| 11 Hours Post-Dose | 2.1 ± 1.52 | 1.9 ± 1.40 | 1.9 ± 1.48 | 2.4 ± 1.34 | 1.4 ± 1.32 | 0.8 ± 1.34 | 0.8 ± 1.34 |
| 12 Hours Post-Dose | 2.2 ± 1.55 | 1.9 ± 1.46 | 2.0 ± 1.51 | 2.2 ± 1.45 | 1.6 ± 1.39 | 0.8 ± 1.34 | 0.8 ± 1.34 |
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). At each post-dose time point, participants check the appropriate box (from 0 to 4) on the Categorical Pain Relief Rating Scale to indicate the relief from starting pain at the post dose time points.
| Scores on a scale | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| Peak Pain Relief Score | 3.3 ± 0.62 | 3.2 ± 0.78 | 3.0 ± 0.82 | 3.1 ± 0.66 | 2.6 ± 1.01 | 1.6 ± 1.55 | 1.3 ± 1.39 |
Global assessment is performed either at 12 hours post-dose or immediately prior to the first intake of rescue medication. Global assessment is based on the question 'Overall, I would rate the study medication I received: 0=Poor, 1=Fair, 2=Good, 3=Very Good, 4=Excellent.'
| Participants | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| Poor (0) | 1 | 1 | 1 | 1 | 4 | 8 | 10 |
| Fair (1) | 2 | 1 | 4 | 2 | 5 | 1 | 2 |
| Good (2) | 5 | 6 | 9 | 7 | 6 | 4 | 1 |
| Very Good (3) | 18 | 14 | 13 | 17 | 14 | 2 | 3 |
| Excellent (4) | 6 | 9 | 5 | 5 | 3 | 1 | 0 |
| Participants | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events | 6 | 3 | 1 | 2 | 3 | 5 | 4 |
| Participants | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| The Number of Participants With Clinically Significant Changes in Physical Examinations and Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Up to 5 days post-dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium/Caffeine-Dose 1 | 0/32 (0%) | 0/32 (0%) | 6/32 (18.8%) |
| Naproxen Sodium/Caffeine-Dose 2 | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| Naproxen Sodium/Caffeine-Dose 3 | 0/32 (0%) | 0/32 (0%) | 1/32 (3.1%) |
| Naproxen Sodium/Caffeine-Dose 4 | 0/32 (0%) | 0/32 (0%) | 2/32 (6.3%) |
| Naproxen Sodium | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| Caffeine | 0/16 (0%) | 0/16 (0%) | 5/16 (31.3%) |
| Placebo | 0/17 (0%) | 0/17 (0%) | 4/17 (23.5%) |
| Event | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/32 | 1/32 | 0/32 | 2/32 | 2/32 | 4/16 | 0/17 |
| HeadacheNervous system disorders | 0/32 | 0/32 | 0/32 | 0/32 | 0/32 | 2/16 | 0/17 |
| VomitingGastrointestinal disorders | 2/32 | 0/32 | 0/32 | 0/32 | 0/32 | 1/16 | 2/17 |
| Ear painEar and labyrinth disorders | 0/32 | 0/32 | 0/32 | 0/32 | 0/32 | 1/16 | 0/17 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/32 | 0/32 | 1/32 | 0/32 | 0/32 | 0/16 | 0/17 |
| Cold sweatSkin and subcutaneous tissue disorders | 0/32 | 0/32 | 0/32 | 0/32 | 0/32 | 1/16 | 0/17 |
| Chest discomfortGeneral disorders | 0/32 | 0/32 | 0/32 | 0/32 | 0/32 | 0/16 | 1/17 |
| DizzinessNervous system disorders | 1/32 | 1/32 | 0/32 | 1/32 | 0/32 | 0/16 | 1/17 |
| Paranasal sinus discomfortRespiratory, thoracic and mediastinal disorders | 0/32 | 0/32 | 0/32 | 0/32 | 0/32 | 0/16 | 1/17 |
| TachycardiaCardiac disorders | 0/32 | 0/32 | 0/32 | 0/32 | 1/32 | 0/16 | 0/17 |
| Age, Continuous(years) | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 17.0 ± 1.03 | 17.4 ± 2.42 | 17.1 ± 1.34 | 17.3 ± 1.49 | 17.9 ± 2.74 | 17.3 ± 1.70 | 17.7 ± 1.40 | 17.4 ± 1.86 |
| Sex: Female, Male(Participants) | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 13 | 14 | 16 | 10 | 14 | 5 | 5 | 77 |
| Male | 19 | 18 | 16 | 22 | 18 | 11 | 12 | 116 |
| Ethnicity (NIH/OMB)(Participants) | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 3 | 2 | 3 | 0 | 10 |
| Not Hispanic or Latino | 30 | 32 | 32 | 29 | 30 | 13 | 17 | 183 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline Pain Intensity Score(Participants) | Naproxen Sodium/Caffeine-Dose 1 | Naproxen Sodium/Caffeine-Dose 2 | Naproxen Sodium/Caffeine-Dose 3 | Naproxen Sodium/Caffeine-Dose 4 | Naproxen Sodium | Caffeine | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| No Pain (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mild Pain (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Moderate Pain (2) | 15 | 13 | 12 | 11 | 11 | 3 | 5 | 70 |
| Severe Pain (3) | 17 | 19 | 20 | 21 | 21 | 13 | 12 | 123 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Nov 2019 to primary completion in Mar 2020, 3 months.
Results were first posted in Jun 2021, 1 year 3 months after primary completion.
Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 3 months is below that.
Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naproxen · Caffeine